{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T14:24:49Z","timestamp":1779891889914,"version":"3.53.1"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,13]]},"abstract":"<jats:p>This retrospective cohort study aims to examine the association between adherence to thiazolidinedione (TZD) therapy and the risk of all-cause mortality and cardiovascular (CV) outcomes in patients with type 2 diabetes mellitus, compared with utilization of dipeptidyl peptidase-4 (DPP-4) inhibitors and sulfonylureas (SUs), using real-world national data from the Korean National Health Insurance Service (2009\u20132018). Two matched cohorts were established: TZDs versus DPP-4 inhibitors (n\u2005=\u20057875) and TZDs versus SUs (n\u2005=\u20055837). Adherence was measured using the proportion of days covered during the first year, with high adherence defined as proportion of days covered \u22650.8. Outcomes included myocardial infarction, stroke, CV death, hospitalization for heart failure, major adverse CV events, and all-cause mortality. Cox proportional hazards models were applied using intention-to-treat and adherence-stratified analyses. At 12 months, DPP-4 inhibitor users demonstrated higher adherence and persistence compared to the TZD users, whereas adherence was comparable between TZD and SU users. In cohort 1, TZD therapy was associated with increased risks of stroke (hazard ratio [HR] 1.14, 95% confidence interval [CI] 1.01\u20131.23) and all-cause mortality (HR 1.10, 95% CI: 1.01\u20131.20) compared with DPP-4 inhibitors. In cohort 2, TZDs were associated with lower risks of myocardial infarction (HR 0.80, 95% CI: 0.65\u20130.99), major adverse CV events (HR 0.85, 95% CI: 0.76\u20130.95), hospitalization for heart failure (HR 0.86, 95% CI: 0.75\u20131.00), and all-cause mortality (HR 0.83, 95% CI: 0.74\u20130.93) compared with SUs. High adherence to TZDs was consistently associated with more favorable CV and survival outcomes, in comparison to SUs. In this nationwide cohort, TZD therapy, especially with high adherence, reduced CV risk and mortality compared with SUs and DPP-4 inhibitors, highlighting the importance of sustained TZD adherence for optimal long-term outcomes in routine clinical practice.<\/jats:p>","DOI":"10.1097\/md.0000000000048016","type":"journal-article","created":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T20:00:22Z","timestamp":1773432022000},"page":"e48016","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Effect of antidiabetic medication adherence on risk of all-cause mortality and cardiovascular diseases in type 2 diabetes patients: Impact of antidiabetic adherence on cardiovascular disease"],"prefix":"10.1097","volume":"105","author":[{"given":"Da Hea","family":"Seo","sequence":"first","affiliation":[{"name":"Division of Endocrinology, Department of Internal Medicine, Inha University College of Medicine, Incheon, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoung Hwa","family":"Ha","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine, Yonsei University College of Medicine, Seoul, Korea"},{"name":"Yonsei Institute for Digital Health, Yonsei University, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2554-3664","authenticated-orcid":false,"given":"So Hun","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Department of Internal Medicine, Inha University College of Medicine, Incheon, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1025-2044","authenticated-orcid":false,"given":"Dae Jung","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, Korea."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20260506","doi-asserted-by":"crossref","first-page":"61","DOI":"10.5334\/gh.1273","article-title":"Impact of persistent medication adherence and compliance with lifestyle recommendations on major cardiovascular events and one-year mortality in patients with type 2 diabetes and advanced stages of atherosclerosis: results from a prospective cohort study.","volume":"18","author":"Shalaeva","year":"2023","journal-title":"Glob Heart"},{"key":"R3-20260506","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/dom.14603","article-title":"Adherence to and persistence with antidiabetic medications and associations with clinical and economic outcomes in people with type 2 diabetes mellitus: a systematic literature review.","volume":"24","author":"Evans","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"R4-20260506","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.2337\/dci24-0035","article-title":"Polypharmacy in type 2 diabetes: appropriate or cause for concern?","volume":"47","author":"Saeed","year":"2024","journal-title":"Diabetes Care"},{"key":"R5-20260506","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13098-022-00785-1","article-title":"Adherence and persistence rates of major antidiabetic medications: a review.","volume":"14","author":"Lee","year":"2022","journal-title":"Diabetol Metab Syndr"},{"key":"R6-20260506","doi-asserted-by":"crossref","first-page":"12190","DOI":"10.1038\/s41598-018-30740-y","article-title":"Effect of medication adherence on long-term all-cause-mortality and hospitalization for cardiovascular disease in 65,067 newly diagnosed type 2 diabetes patients.","volume":"8","author":"Kim","year":"2018","journal-title":"Sci Rep"},{"key":"R7-20260506","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1185\/03007995.2015.1053048","article-title":"Meta-analysis of studies examining medication adherence, persistence, and discontinuation of oral antihyperglycemic agents in type 2 diabetes.","volume":"31","author":"Iglay","year":"2015","journal-title":"Curr Med Res Opin"},{"key":"R8-20260506","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.2337\/dc16-1925","article-title":"Association between adherence to pharmacotherapy and outcomes in type 2 diabetes: a meta-analysis.","volume":"40","author":"Khunti","year":"2017","journal-title":"Diabetes Care"},{"key":"R9-20260506","doi-asserted-by":"crossref","first-page":"107931","DOI":"10.1016\/j.jdiacomp.2021.107931","article-title":"Non-adherence to antidiabetic and cardiovascular drugs in type 2 diabetes mellitus and its association with renal and cardiovascular outcomes: a narrative review.","volume":"35","author":"Denicol\u00f2","year":"2021","journal-title":"J Diabetes Complications"},{"key":"R10-20260506","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.eprac.2025.04.004","article-title":"Reassessing the risk-benefit profile of thiazolidinediones: cardiovascular risks and stroke prevention through real-world data.","volume":"31","author":"Fei","year":"2025","journal-title":"Endocrine Pract"},{"key":"R11-20260506","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3803\/EnM.2016.31.3.349","article-title":"The diabetes epidemic in Korea.","volume":"31","author":"Noh","year":"2016","journal-title":"Endocrinol Metabol (Seoul, Korea)"},{"key":"R12-20260506","first-page":"799","article-title":"Data resource profile: the national health information database of the national health insurance service in South Korea.","volume":"46","author":"Cheol Seong","year":"2017","journal-title":"Int J Epidemiol"},{"issue":"10 Suppl","key":"R14-20260506","first-page":"S249","article-title":"Measuring patient persistency with drug therapy using methods for the design and analysis of natural history studies.","volume":"8","author":"Johnson","year":"2002","journal-title":"Am J Manag Care"},{"key":"R15-20260506","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1001\/jama.297.2.177","article-title":"Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction.","volume":"297","author":"Rasmussen","year":"2007","journal-title":"JAMA"},{"key":"R16-20260506","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0895-4356(00)00321-8","article-title":"Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores.","volume":"54","author":"Normand","year":"2001","journal-title":"J Clin Epidemiol"},{"key":"R17-20260506","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.3390\/jcm12051981","article-title":"Adherence to oral antidiabetic drugs in patients with type 2 diabetes: systematic review and meta-analysis.","volume":"12","author":"Piragine","year":"2023","journal-title":"J Clin Med"},{"key":"R18-20260506","doi-asserted-by":"crossref","first-page":"15781","DOI":"10.1038\/s41598-020-72967-8","article-title":"Assessing the need for pioglitazone in the treatment of patients with type 2 diabetes: a meta-analysis of its risks and benefits from prospective trials.","volume":"10","author":"Sinha","year":"2020","journal-title":"Sci Rep"},{"key":"R19-20260506","doi-asserted-by":"crossref","first-page":"e037950","DOI":"10.1161\/JAHA.124.037950","article-title":"Thiazolidinedione use and cardiovascular outcomes in patients with type 2 diabetes who underwent carotid artery revascularization.","volume":"14","author":"Kim","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"R20-20260506","doi-asserted-by":"crossref","first-page":"111745","DOI":"10.1016\/j.diabres.2024.111745","article-title":"Adherence and persistence to novel glucose-lowering medications in persons with type 2 diabetes mellitus undergoing routine care.","volume":"213","author":"O\u2019Hara","year":"2024","journal-title":"Diabetes Res Clin Pract"},{"key":"R21-20260506","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.mayocp.2024.08.015","article-title":"Cardiovascular outcomes with antidiabetic drugs in people with type 2 diabetes and a prior stroke.","volume":"100","author":"Bae","year":"2025","journal-title":"Mayo Clin Proc"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000048016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T12:05:24Z","timestamp":1778069124000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000048016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":19,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000048016","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,13]]},"assertion":[{"value":"2025-09-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-20","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}